Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors.
Yusra F. Shao(Wayne State University), Justin C. Moser(HonorHealth), Geoffrey T. Gibney(Georgetown University), Dave S.�B. Hoon(Saint John's Health Center), Ari M. Vanderwalde(West Cancer Center), Takami Sato(Thomas Jefferson University), Sourat Darabi(Hoag Memorial Hospital Presbyterian), Evidio Domingo‐Musibay(University of Minnesota), Yasmine Baca(Caris Life Sciences (United States)), Joanne Xiu(Caris Life Sciences (United States)), Gino K. In(University of Southern California), Burton Eisenberg(Hoag Memorial Hospital Presbyterian), Hirva Mamdani(Wayne State University)
Cited by 1
Related Papers
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431